Compare Abeona Therapeutics Inc (ABEO) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs UnitedHealth Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while UnitedHealth Group Inc trades at $425.14 (market cap $388.86B). The key difference: UnitedHealth Group Inc is far larger — about 1041.6× Abeona Therapeutics Inc's market cap, and UnitedHealth Group Inc pays a 2.17% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | UNH | |
|---|---|---|
Market Cap | $373.32M | $388.86B |
Sector | Health | Health |
52-Week High | $7.23 | $428.19 |
52-Week Low | $4.17 | $237.77 |
Enterprise Value | $228.22M | $435.55B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
UnitedHealth Group (UNH) trades at $417.99, down 1.73% today, but maintains a bullish technical signal with strong moving averages and support near $414. Revenue grew to $447.57B in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
Outlook remains positive with analyst consensus at Buy (82.69%) and a $419.47 price target, though regulatory risks from lawsuits and margin pressures pose challenges. The stock's valuation at a P/E of 31.48 appears rich relative to historical norms, requiring sustained earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
